$25.16
2.71% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

IDEAYA Biosciences Inc Stock price

$25.16
-1.83 6.78% 1M
-9.21 26.80% 6M
-10.42 29.29% YTD
-10.18 28.81% 1Y
+1.87 8.03% 3Y
+16.66 196.00% 5Y
+13.97 124.84% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.70 2.71%
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

Key metrics

Market capitalization $2.17b
Enterprise Value $1.27b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 324.84
P/S ratio (TTM) P/S ratio 554.75
P/B ratio (TTM) P/B ratio 1.84
Revenue growth (TTM) Revenue growth -83.30%
Revenue (TTM) Revenue $3.92m
EBIT (operating result TTM) EBIT $-224.75m
Free Cash Flow (TTM) Free Cash Flow $-153.27m
Cash position $920.03m
EPS (TTM) EPS $-2.33
P/E forward negative
P/S forward 378.19
EV/Sales forward 221.46
Short interest 11.52%
Show more

Is IDEAYA Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

IDEAYA Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a IDEAYA Biosciences Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a IDEAYA Biosciences Inc forecast:

Buy
93%
Hold
7%

Financial data from IDEAYA Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.92 3.92
83% 83%
100%
- Direct Costs 4.22 4.22
21% 21%
108%
-0.29 -0.29
101% 101%
-7%
- Selling and Administrative Expenses 27 27
35% 35%
689%
- Research and Development Expense 193 193
67% 67%
4,930%
-221 -221
91% 91%
-5,626%
- Depreciation and Amortization 4.22 4.22
21% 21%
108%
EBIT (Operating Income) EBIT -225 -225
89% 89%
-5,733%
Net Profit -178 -178
73% 73%
-4,544%

In millions USD.

Don't miss a Thing! We will send you all news about IDEAYA Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEAYA Biosciences Inc Stock News

Neutral
PRNewsWire
2 days ago
SOUTH SAN FRANCISCO, Calif. , Dec. 27, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on December 26, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 31,400 shares of the Co...
Neutral
PRNewsWire
12 days ago
Independent Data Monitoring Committee (IDMC) recommends move-forward dose in Part 2a of potential registration-enabling trial in 1L HLA-A2-Negative MUM, based on clinical efficacy and safety observed Over 185 patients enrolled in potential registration-enabling trial in 1L HLA-A2-Negative MUM, and the darovasertib and crizotinib combination has received U.S. Food and Drug Administration (FDA) F...
Neutral
PRNewsWire
13 days ago
Nominated development candidate IDE251, a potential first-in-class KAT6/7 inhibitor IDE251 is targeted to be evaluated in breast and NSCLC with 8p11 amplification, and in the setting of lineage addiction. 8p11 amplification prevalence is projected to be ~15% in breast cancer and ~17.5% in squamous NSCLC Demonstrated robust and durable monotherapy anti-tumor activity in multiple biomarker positi...
More IDEAYA Biosciences Inc News

Company Profile

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Yujiro Hata
Employees 124
Founded 2015
Website www.ideayabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today